MDT

99.36

+1.42%↑

146.53

+0.24%↑

VEEV

219.29

+0.75%↑

HQY

88.47

+3.78%↑

NEOG

9.51

+3.71%↑

MDT

99.36

+1.42%↑

146.53

+0.24%↑

VEEV

219.29

+0.75%↑

HQY

88.47

+3.78%↑

NEOG

9.51

+3.71%↑

MDT

99.36

+1.42%↑

146.53

+0.24%↑

VEEV

219.29

+0.75%↑

HQY

88.47

+3.78%↑

NEOG

9.51

+3.71%↑

MDT

99.36

+1.42%↑

146.53

+0.24%↑

VEEV

219.29

+0.75%↑

HQY

88.47

+3.78%↑

NEOG

9.51

+3.71%↑

MDT

99.36

+1.42%↑

146.53

+0.24%↑

VEEV

219.29

+0.75%↑

HQY

88.47

+3.78%↑

NEOG

9.51

+3.71%↑

Home・Akcijų sąrašas・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Atidarymo kaina

7.02 2.03

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

6.71

Max

7.11

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-2.2M -10M
Darbuotojai	31
EBITDA	131K -10M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+97.48% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-03-24

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-68M 504M
Ankstesnė atidarymo kaina	4.99
Ankstesnė uždarymo kaina	7.02

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

3.165 / 3.5827 Palaikymas ir pasipriešinimas

Corvus Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-01-14 22:41; UTC

Įsigijimai, susijungimai, perėmimai

Canadian Natural Resources, Tourmaline File Deal Notice With Antitrust Regulator

2026-01-15 00:00; UTC

Uždarbis

Welcome to Greenland, an Economy Reliant on Subsidies and Shrimp -- WSJ

2026-01-14 23:47; UTC

Rinkos pokalbiai

Oil Slips After Trump Appears to Tilt Away From Military Action in Iran -- Market Talk

2026-01-14 23:44; UTC

Rinkos pokalbiai

Nikkei May Decline After Hitting Record Highs; Election in Focus -- Market Talk

2026-01-14 23:39; UTC

Rinkos pokalbiai

ANZ's New Bull Still Sees Valuation Gap to Peers -- Market Talk

2026-01-14 23:32; UTC

Rinkos pokalbiai

Gold Declines on Likely Technical Correction, Possible Profit-Taking -- Market Talk

2026-01-14 22:56; UTC

Įsigijimai, susijungimai, perėmimai

Soho House Amends Rollover and Support Agreements With Broad Street Principal Investments and Others

2026-01-14 22:53; UTC

Įsigijimai, susijungimai, perėmimai

Soho House: Apollo Global Management and Goldman Sachs Asset Management Amend Debt Commitment

2026-01-14 22:17; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-01-14 22:17; UTC

Rinkos pokalbiai

WiseTech's Revenue Growth Drivers Attract Scrutiny -- Market Talk

2026-01-14 22:09; UTC

Uždarbis

CITIC Securities: Uptrend in China Capital Markets Supported Results >600030.SH

2026-01-14 22:08; UTC

Uždarbis

CITIC Securities 2025 Oper Rev CNY74.83B Vs. CNY58.12B >600030.SH

2026-01-14 22:08; UTC

Uždarbis

CITIC Securities 2025 Net CNY30.05B Vs. Net CNY21.57B >600030.SH

2026-01-14 21:53; UTC

Įsigijimai, susijungimai, perėmimai

WuXi XDC Expects 2025 Net to Increase Over 38% on Year

2026-01-14 21:53; UTC

Įsigijimai, susijungimai, perėmimai

WuXi XDC Expects 2025 Revenue to Increase More Than 45% on Year

2026-01-14 21:52; UTC

Įsigijimai, susijungimai, perėmimai

WuXi XDC Announces Positive Profit Alert for 2025

2026-01-14 21:51; UTC

Įsigijimai, susijungimai, perėmimai

Citigroup Acting as Financial Advisor to WuXi XDC

2026-01-14 21:51; UTC

Įsigijimai, susijungimai, perėmimai

WuXi XDC: Aims to Keep Listing Status of BioDlink

2026-01-14 21:51; UTC

Įsigijimai, susijungimai, perėmimai

WuXi XDC: Company to Finance BioDlink Shares Acquisition via Internal Resources

2026-01-14 21:50; UTC

Rinkos pokalbiai

Uždarbis

Financial Services Roundup: Market Talk

2026-01-14 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-01-14 21:49; UTC

Įsigijimai, susijungimai, perėmimai

WuXi XDC: BioDlink Offer to Cost HK$2.79B

2026-01-14 21:48; UTC

Įsigijimai, susijungimai, perėmimai

WuXi XDC Offers to Pay HK$4.00 for Each BioDlink International Share

2026-01-14 21:48; UTC

Įsigijimai, susijungimai, perėmimai

WuXi XDC Makes Cash Offer for BioDlink International

2026-01-14 21:13; UTC

Rinkos pokalbiai

Oil Retreats Late After Trump Comments on Iran -- Market Talk

2026-01-14 20:30; UTC

Rinkos pokalbiai

Uždarbis

Danaher's Preliminary 4Q Seen as Promising -- Market Talk

2026-01-14 20:13; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Sink Ahead of Storage Report -- Market Talk

2026-01-14 20:08; UTC

Rinkos pokalbiai

Oil Futures Extend Rally on Iran Tensions -- Market Talk

2026-01-14 19:33; UTC

Rinkos pokalbiai

Nutrien Seen as Winner in Tighter 2026 Potash Market, Higher Prices -- Market Talk

2026-01-14 19:06; UTC

Rinkos pokalbiai

Uždarbis

Wells Fargo Says Customers, Economy Remain Resilient -- Market Talk

Akcijų palyginimas

Kainos pokytis

Corvus Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

97.48% į viršų

12 mėnesių prognozė

Vidutinis 13.33 USD 97.48%

Aukščiausias 16 USD

Žemiausias 11 USD

Remiantis 3 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Corvus Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

3 ratings

Pirkti

Laikyti

Parduoti

Remiantis 3 analitikų, pateikusių Corvus Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

3.165 / 3.5827Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bearish.

Bearish events outweigh bullish events.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.